Teva seeks to extend Embeda supply deal with Pfizer

Israeli drugmaker Teva Pharmaceutical Industries (NYSE: TEVA) has asked the US Federal Trade Commission (FTC) to modify the ruling that it made in relation to the 2012 merger of Watson Pharmaceuticals and Actavis.

The FTC alleged that the merger risked reducing competition in the USA for a number of generics, including the copy of Pfizer’s (NYSE: PFE) abuse-resistant opioid painkiller sold under the brand name Embeda (morphine sulfate and naltrexone hydrochloride).

In its ruling, the FTC ordered Watson and Actavis to supply Embeda to Pfizer for a period limited at four years after the US pharma giant’s relaunch of the drug, which occurred in January 2015.